BioXCell熱銷產品--RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)

時間：2024/1/23閱讀：339

產品描述：

9D9-CP008單克隆抗體是原始9D9單克隆抗體的重組嵌合型抗體,?？勺兘Y構域序列與原始9D9克隆號相同,，但是恒定區(qū)序列已經從小鼠IgG2b變?yōu)樾∈驣gG2a,。9D9-CP008單克隆抗體在Fc片段中也含有LALA-PG突變,，使其無法與內源性Fcγ受體結合,。

9D9-CP008單克隆抗體能與小鼠CTLA-4(細胞毒性T淋巴細胞抗原-4)反應,，CTLA-4也稱為CD152,。CTLA-4是一種33 kDa的細胞表面受體，由屬于免疫球蛋白超家族CD28家族的Ctla4基因編碼,。CTLA-4在活化的T淋巴細胞和B淋巴細胞上表達,。CTLA-4在結構上類似于T細胞共刺激蛋白CD28，兩種分子都與B7家族成員B7-1 (CD80)和B7-2 (CD86)結合,。在與配體結合時,，CTLA-4負調節(jié)細胞介導的免疫反應。CTLA-4在誘導和/或維持免疫耐受,、胸腺細胞發(fā)育和保護性免疫調節(jié)中起作用,。CTLA-4在免疫下調中的關鍵作用已經在CTLA-4缺陷小鼠中得到證實，這些小鼠在3-5周齡時由于淋巴增生性疾病的發(fā)展而死亡,。CTLA-4目前是腫瘤免疫治療中的熱門免疫檢查點靶點之一,。

產品詳情：

產品名稱	RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)/欣博盛生物
產品貨號	CP008
產品規(guī)格	1mg
反應種屬	Mouse
克隆號	9D9-CP008
同種型	Mouse IgG2b(switched from mouse IgG2a)
免疫原	Not available or unknown
實驗應用	in vivo CTLA-4 neutralization* Western blot* *Reported for the original mouse IgG2b 9D9 antibody
產品形式	PBS, pH 7.0,Contains no stabilizers or preservatives
純度	>95%, Determined by SDS-PAGE
聚合	<5%, Determined by SEC
無菌處理	0.2 µm filtration
純化方式	Protein A
分子量	150 kDa
小鼠病原檢測	Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative
保存條件	抗體原液保存在4°C，不能冷凍保存,。
推薦抗體稀釋液	InVivoPure pH 7.0 Dilution Buffer（貨號IP0070）

該產品自上市已被多篇SCI文獻引用,，品質有保證，以下是部分已發(fā)表的文獻引用：

應用

文章

體內CTLA-4中和

(in vivo CTLA-4

neutralization)

1. Dai, M., et al. (2015). 'Curing mice with large tumors by locally

delivering combinations of immunomodulatory antibodies'

Clin Cancer Res 21(5): 1127-1138.

2. Zippelius, A., et al. (2015). 'Induced PD-L1 expression mediates

acquired resistance to agonistic anti-CD40 treatment' Cancer Immunol

Res 3(3): 236-244.

3. Redmond, W. L., et al. (2014). 'Combined targeting of costimulatory

(OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T

cells capable of driving robust antitumor immunity' Cancer Immunol

Res 2(2): 142-153.

4. Condamine, T., et al. (2014). 'ER stress regulates myeloid-derived

suppressor cell fate through TRAIL-R-mediated apoptosis' J Clin Invest

124(6): 2626-2639.

5. Muller, P., et al. (2014). 'Microtubule-depolymerizing agents used in

antibody-drug conjugates induce antitumor immunity by stimulation of

dendritic cells' Cancer Immunol Res 2(8): 741-755.

6. Bulliard, Y., et al. (2013). 'Activating Fc gamma receptors contribute

to the antitumor activities of immunoregulatory receptor-targeting

antibodies' J Exp Med 210(9): 1685-1693.

BioXCell熱銷產品--RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)

更多產品詳情請聯(lián)系 BioXCell 中國授權代理——欣博盛生物

BioXCell熱銷產品--RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)

會員登錄

收藏該商鋪

提示